WIM
LCTX icon

Warwick Investment Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Warwick Investment Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.8K Buy
+11,300
New +$15.6K ﹤0.01% 148

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Warwick Investment Management's LCTX Position: Q2 2026 in Review

Warwick Investment Management opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 11,300 shares worth $14.8K. The stake represents ﹤0.01% of the portfolio and ranks #148 among its holdings.

132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Warwick Investment Management held 11,300 shares of Lineage Cell Therapeutics worth $14.8K as of Q2 2026.
  • Lineage Cell Therapeutics was a new Warwick Investment Management position in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Warwick Investment Management's portfolio in Q2 2026, its #148 holding.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Warwick Investment Management's 13F filing for Q2 2026, filed 31 Jul 2026.